Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
Ardelyx reported strong first quarter 2026 growth while remaining loss-making. Total product revenue reached $93.4 million for the quarter ended March 31, 2026, up 38% from $67.8 million a year earlier, driven mainly by IBSRELA sales of $70.1 million, which grew 58% year-over-year.
XPHOZAH contributed $23.3 million in revenue, and total revenue including other items was $94.5 million. Operating expenses rose as Ardelyx invested in commercialization and R&D, leading to a net loss of $37.6 million, or $(0.15) per share, slightly improved from a $41.1 million loss a year earlier. The company ended the quarter with $238.1 million in cash, cash equivalents and short-term investments and reiterated 2026 revenue guidance of $410–$430 million for IBSRELA and $110–$120 million for XPHOZAH, while advancing its pipeline, including the Phase 3 ACCEL trial in chronic idiopathic constipation and preclinical candidate RDX10531.
Ardelyx, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 16, 2026 at 8:30 a.m. Eastern Time. Holders of common stock as of April 22, 2026 can vote online, by phone, mail, or during the live webcast.
Stockholders will vote on electing three Class III directors, an advisory Say‑on‑Pay resolution, how often to hold future Say‑on‑Pay votes, ratification of Ernst & Young LLP as auditor for 2026, and an amendment to the 2014 Equity Incentive Award Plan to add 9,000,000 shares. Ardelyx highlights strong governance practices, including an independent chair, fully independent board committees, a classified board structure, and extensive pay‑for‑performance features and clawback, ownership, and anti‑hedging policies.
Ardelyx, Inc. Schedule 13G/A discloses passive institutional holdings by Millennium-related entities and Integrated Core Strategies. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report 18,043,970 shares (7.4%) and Integrated Core Strategies (US) LLC reports 17,721,732 shares (7.2%). The filing is a joint filing documented by a April 24, 2026 Joint Filing Agreement.
ARDELYX, INC. filed an initial ownership report for Chief Legal Officer Felecia Ettenberg. The filing shows direct ownership of 237,000 shares of Common Stock.
It also reports a stock option to buy 355,000 shares of Common Stock at an exercise price of $6.30 per share, expiring on April 20, 2036. According to the vesting schedule, 25% of the option vests on April 20, 2027, with the remaining shares vesting in 36 equal monthly installments if her employment continues. Footnotes further note restricted stock units that convert into one share of Common Stock for each unit upon vesting.
ARDELYX, INC. President & CEO Michael Raab exercised stock options and sold shares in a planned transaction. He exercised options for 20,834 shares of common stock at an exercise price of $0.99 per share, then sold 41,668 common shares at a weighted average price of $6.2867 per share pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, he holds 1,795,614 shares directly, plus additional indirect holdings of 24,364 and 1,000 shares held in family trusts.
ARDELYX, INC. Chief Medical Officer Dinavahi Rajani reported her equity holdings in connection with a Form 3 filing. She holds stock options to purchase 301,000 shares of Common Stock at an exercise price of $6.11 per share, expiring on April 1, 2036.
She also directly holds 201,000 shares of Common Stock. The option grant vests over time, with 25% of the shares vesting on April 1, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to her continued employment or service with the company.
Ardelyx Inc received an amended Schedule 13G/A from The Vanguard Group reporting that, following an internal realignment, Vanguard and its subsidiaries/ divisions will report holdings separately. The filing states amount beneficially owned: 0 and percent of class: 0% as of 03/13/2026.
The amendment cites SEC Release No. 34-39538 (January 12, 1998) and explains that certain Vanguard subsidiaries that formerly were reported under The Vanguard Group, Inc. will now report on a disaggregated basis. The signing official is Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
ARDELYX, INC. President & CEO Michael Raab exercised stock options to acquire 20,833 shares of common stock at $0.99 per share, then sold 41,666 shares at a weighted average price of $5.84 per share under a pre-arranged Rule 10b5-1 trading plan.
After these transactions, he held 1,816,448 common shares directly and 374,168 stock options of this award, plus indirect holdings of 24,364 and 1,000 shares through family trusts for his children.
ARDELYX, INC. President & CEO Michael Raab reported option exercises and share sales in ARDX. He exercised stock options for 20,833 shares of common stock at an exercise price of $0.99 per share through a derivative conversion. The resulting 20,833 common shares were acquired and then partially offset by an open-market sale of 41,666 common shares at a weighted average price of $6.255 per share, executed in multiple trades between $6.08 and $6.56. The sale was made under a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, Raab directly held 1,836,153 common shares, with additional shares held indirectly through family trusts for his children.